Liu, BZhou, TGeng, JZhang, FWang, JLi, Y2015-12-302015-12-302015-12Liu B, Zhou T, Geng J, Zhang F, Wang J, Li Y. Percutaneous computed tomography‑guided iodine‑125 seeds implantation for unresectable pancreatic cancer. Indian Journal of Cancer. 2015 Dec; 52(6)Suppl_2: s69-s74.http://imsear.searo.who.int/handle/123456789/169243BACKGROUND: To examine the safety and clinical efficacy of computed tomography (CT)‑guided radioactive iodine‑125 (125I) seeds implantation for patients with unresectable pancreatic cancer. MATERIALS AND METHODS: A group of 26 patients with pathologically confirmed unresectable pancreatic cancer underwent percutaneous CT‑guided 125I seeds implantation. Part of them received transarterial chemotherapy and/or percutaneous transhepatic cholangial drainage before or after seeds implantation. The primary endpoints were the objective response rates, local control rates, and overall survival. RESULTS: CT scan 2 months after treatment revealed complete response (CR) in 8 patients, partial response (PR) in 9 patients. Overall response rate (CR + PR) is 65.38%. Local control rate was 88.46%. Median survival of the whole group was 15.3 months, whereas for Stage III and IV was 17.6 and 9.1 months, respectively. The estimated 1‑year survival was 30.77%. CONCLUSIONS: We consider CT‑guided 125I seeds implantation as a safe, effective, uncomplicated treatment for unresectable pancreatic cancer.enBrachytherapyiodinepancreas cancerradioisotopesArticle